Role of 18F-FDG-PET/CT in the staging of metastatic rhabdomyosarcoma: a report from the European paediatric Soft tissue sarcoma Study Group

2021 ◽  
Vol 155 ◽  
pp. 155-162
Author(s):  
Federico Mercolini ◽  
Pietro Zucchetta ◽  
Nina Jehanno ◽  
Nadege Corradini ◽  
Rick R. Van Rijn ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Fdg Pet ◽  
Study Group ◽  
European Paediatric ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

The role of 18F-FDG PET/CT in soft tissue sarcoma

2019 ◽  
Vol 40 (6) ◽  
pp. 626-631 ◽  
Author(s):  
Andrea Sambri ◽  
Giuseppe Bianchi ◽  
Alessandra Longhi ◽  
Alberto Righi ◽  
Davide Maria Donati ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Fdg Pet ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals Volume of interest delineation techniques for 18F-FDG PET-CT scans during neoadjuvant extremity soft tissue sarcoma treatment in adults: a feasibility study

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Marc G. Stevenson ◽  
Lukas B. Been ◽  
Harald J. Hoekstra ◽  
Albert J. H. Suurmeijer ◽  
Ronald Boellaard ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Fdg Pet ◽  
Ct Scans ◽  
Volume Of Interest ◽  
Extremity Soft Tissue Sarcoma ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Sarcoma Treatment

Prognostic value of 18F-FDG PET/CT in patients with soft tissue sarcoma: comparisons between metabolic parameters

2014 ◽  
Vol 43 (5) ◽  
pp. 641-648 ◽  
Author(s):  
Sun-pyo Hong ◽  
Seung Eun Lee ◽  
Yoon-La Choi ◽  
Sung Wook Seo ◽  
Ki-Sun Sung ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Fdg Pet ◽  
Prognostic Value ◽  
Metabolic Parameters ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Total lesion glycolysis by 18F-FDG PET/CT is a reliable predictor of prognosis in soft-tissue sarcoma

2013 ◽  
Vol 40 (12) ◽  
pp. 1836-1842 ◽  
Author(s):  
Eun-Seok Choi ◽  
Seung-Gyun Ha ◽  
Han-Soo Kim ◽  
Jae Hong Ha ◽  
Jin Chul Paeng ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Fdg Pet ◽  
Total Lesion Glycolysis ◽  
Reliable Predictor ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals Assessing the role of 18F-FDG PET and 18F-FDG PET/CT in the diagnosis of soft tissue musculoskeletal malignancies: a systematic review and meta-analysis

2015 ◽  
Vol 43 (5) ◽  
pp. 860-870 ◽  
Author(s):  
Elba C. Etchebehere ◽  
Brian P. Hobbs ◽  
Denái R. Milton ◽  
Osama Malawi ◽  
Shreyaskumar Patel ◽  
...  
Keyword(s):  
Systematic Review ◽  
Soft Tissue ◽  
Fdg Pet ◽  
Meta Analysis ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals Prognostic value of 18F-FDG PET-CT-based functional parameters in patients with soft tissue sarcoma

Medicine ◽  
2017 ◽  
Vol 96 (6) ◽  
pp. e5913 ◽  
Author(s):  
Linyan Chen ◽  
Xin Wu ◽  
Xuelei Ma ◽  
Linghong Guo ◽  
Chenjing Zhu ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Fdg Pet ◽  
Prognostic Value ◽  
Functional Parameters ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals Prognostic Value of Quantitative [18F]FDG-PET Features in Patients with Metastases from Soft Tissue Sarcoma

Diagnostics ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. 2271
Author(s):  
Gijsbert M. Kalisvaart ◽  
Willem Grootjans ◽  
Judith V. M. G. Bovée ◽  
Hans Gelderblom ◽  
Jos A. van der Hage ◽  
...  
Keyword(s):  
Overall Survival ◽  
Prognostic Factors ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Fdg Pet ◽  
Prognostic Value ◽  
Adequate Treatment ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Background: Prognostic biomarkers are pivotal for adequate treatment decision making. The objective of this study was to determine the added prognostic value of quantitative [18F]FDG-PET features in patients with metastases from soft tissue sarcoma (STS). Methods: Patients with metastases from STS, detected by (re)staging [18F]FDG-PET/CT at Leiden University Medical Centre, were retrospectively included. Clinical and histopathological patient characteristics and [18F]FDG-PET features (SUVmax, SUVpeak, SUVmean, total lesion glycolysis, and metabolic tumor volume) were analyzed as prognostic factors for overall survival using a Cox proportional hazards model and Kaplan–Meier methods. Results: A total of 31 patients were included. SUVmax and SUVpeak were significantly predictive for overall survival (OS) in a univariate analysis (p = 0.004 and p = 0.006, respectively). Hazard ratios (HRs) were 1.16 per unit increase for SUVmax and 1.20 per unit for SUVpeak. SUVmax and SUVpeak remained significant predictors for overall survival after correction for the two strongest predictive clinical characteristics (number of lesions and performance status) in a multivariate analysis (p = 0.02 for both). Median SUVmax and SUVpeak were 5.7 and 4.9 g/mL, respectively. The estimated mean overall survival in patients with SUVmax > 5.7 g/mL was 14 months; otherwise, it was 39 months (p < 0.001). For patients with SUVpeak > 4.9 g/mL, the estimated mean overall survival was 18 months; otherwise, it was 33 months (p = 0.04). Conclusions: In this study, SUVmax and SUVpeak were independent prognostic factors for overall survival in patients with metastases from STS. These results warrant further investigation of metabolic imaging with [18F]FDG-PET/CT in patients with metastatic STS.

Sign in / Sign up

Export Citation Format

Share Document